| 000 | 01705 a2200433 4500 | ||
|---|---|---|---|
| 005 | 20250517121619.0 | ||
| 264 | 0 | _c20180104 | |
| 008 | 201801s 0 0 eng d | ||
| 022 | _a1873-5010 | ||
| 024 | 7 |
_a10.1016/j.jcf.2016.09.003 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSermet-Gaudelus, Isabelle | |
| 245 | 0 | 0 |
_aBone demineralization is improved by ivacaftor in patients with cystic fibrosis carrying the p.Gly551Asp mutation. _h[electronic resource] |
| 260 |
_bJournal of cystic fibrosis : official journal of the European Cystic Fibrosis Society _c11 2016 |
||
| 300 |
_ae67-e69 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAminophenols _xadministration & dosage |
| 650 | 0 | 4 |
_aBone Demineralization, Pathologic _xetiology |
| 650 | 0 | 4 |
_aBone Density _xdrug effects |
| 650 | 0 | 4 | _aCells, Cultured |
| 650 | 0 | 4 |
_aChloride Channel Agonists _xadministration & dosage |
| 650 | 0 | 4 |
_aCystic Fibrosis _xcomplications |
| 650 | 0 | 4 |
_aCystic Fibrosis Transmembrane Conductance Regulator _xgenetics |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aMutation |
| 650 | 0 | 4 |
_aOsteoblasts _xdrug effects |
| 650 | 0 | 4 |
_aQuinolones _xadministration & dosage |
| 650 | 0 | 4 | _aStatistics as Topic |
| 700 | 1 | _aDelion, Martial | |
| 700 | 1 | _aDurieu, Isabelle | |
| 700 | 1 | _aJacquot, Jacky | |
| 700 | 1 | _aHubert, Dominique | |
| 773 | 0 |
_tJournal of cystic fibrosis : official journal of the European Cystic Fibrosis Society _gvol. 15 _gno. 6 _gp. e67-e69 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.jcf.2016.09.003 _zAvailable from publisher's website |
| 999 |
_c26519540 _d26519540 |
||